BioNano Genomics(MX:BNGO)
MX$69.350.00 (0.00%)
MX:BNGO
BioNano Genomics earnings date
MX$69.35
At close:0.00 (0.00%)
BioNano Genomics (BNGO) Q3 2026 Earnings Report
0 Followers
MX:BNGO Q3 2026 EPS Results
- Actual EPS
- -MXN 8.37
- Consensus EPS
- -MXN 8.37
- Beat/Miss
- Met expectations
- One Year Ago EPS
- -MXN 37.92
MX:BNGO Q3 2026 Revenue Results
- Actual Revenue
- MXN 153.85M
- Expected Revenue
- MXN 156.95M
- Beat/Miss
- Missed by -MXN 3.10M
- YoY Revenue Growth
- +12.34%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/10/2026
- Time
- After Close
- Conference Call
- Tuesday, November 10, 2026
MX:BNGO Upcoming Earnings
BioNano Genomics's next earnings date is estimated for March 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:BNGO Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive, with double-digit revenue and flow cell growth, record quarterly flow cell sales, improving gross margins and operating expenses, expanding reimbursement support, growing clinical adoption, and reiterated full-year guidance. The main challenges were the 31% decline in software revenue, production constraints and back orders, the time required for new clinical sites to reach routine use, and the lack of a current hematologic offering through Bionano Labs.
Company Guidance
For the full year 2026, Bionano reiterated revenue guidance of $31 million to $33 million, representing growth of 9% to 16% over 2025, and expects to land near the midpoint; the company expects adjusted EBITDA neutrality by the end of 2027, while its September framework cited $50 million to $54 million in 2027 revenue and approximately breakeven adjusted EBITDA exiting Q4 as a vision and guideline; production capacity is expected to essentially double about halfway through midyear next year, which the company said will more than meet the capacity for ’27 and also most of ’28, with a plan to be essentially free and clear of any back orders by the end of this year.
- Record Flow Cell Sales and Strong Quarterly Revenue GrowthThird-quarter 2026 revenue was $8.3 million, up 12% compared to Q3 2025. Nanochannel array flow cells sold reached a quarterly record of 9,870 units, up 18% year-over-year, reflecting increased sample processing by customers and growing routine use of OGM.
- Consumables and Instrument Revenue GrowthConsumable revenue was $4.7 million, up 24% year-over-year, driven by sales to existing customers in the Americas. Other revenue, including instruments and services, was $2.5 million, also up 24%, led by higher instrument sales to new customers.
- Geographic Revenue ExpansionRevenue in Europe, the Middle East and Africa grew 14% year-over-year to $4.1 million, driven by growth in instrument revenue. Revenue in the Americas grew 35% year-over-year to $3.8 million.
- Increasing Customer Utilization and Workflow CapacityCustomers reported that software and compute upgrades allowed them to broaden test menus and process more samples. In some cases, customers were able to double weekly cancer sample throughput without changing their hardware.
- Continued Software and Ionic AdoptionVIA software continued to see adoption among NGS and long-read sequencing laboratories, while Ionic remained a key focus for producing high-purity DNA and RNA at scale across OGM and NGS workflows. The company described software offerings as an on-ramp to broader OGM platform adoption.
- Progress Toward OGM Medicare CoverageMolDX published a proposed local coverage determination for OGM-based genome-wide detection of copy number alterations and structural variants in hematologic neoplasms across Medicare Administrative Contractor jurisdictions covering 31 U.S. states. These states represent roughly 61% of the U.S. population, and the company stated that private insurers often align their policies with Medicare coverage.
- Reimbursement Foundation EstablishedThe AMA has approved two Category 1 CPT codes for OGM, covering hematologic malignancies and constitutional genetic disorders, and CMS has established reimbursement rates for both codes.
- Expansion in New York Clinical LaboratoriesThe New York State Department of Health approved OGM-based laboratory-developed tests at University of Rochester Medicine for genetic disorders, reproductive disorders and hematologic malignancies. Memorial Sloan Kettering Cancer Center also launched OGM-based hematologic malignancy testing following state approval.
- Growing Independent Clinical EvidenceThree new independent peer-reviewed publications highlighted potential clinical value for OGM in high-risk myeloid cancers. In a 332-sample MDS study, OGM identified chromoanagenesis in 15.9% of cases overall and 17.6% of newly diagnosed subjects; those subjects had median survival of 9.9 months, while median survival for the rest of the group had not been reached. A University of Oulu study found clinically relevant structural variants in 46% of cytogenetically normal acute myeloid leukemia cases. A Josep Carreras study produced a result in every sample, including all 8 samples where conventional banding failed, and identified 134 additional genomic alterations.
- Broadening Published Evidence BaseThe company stated that 365 studies had been published year-to-date, in addition to the three new publications discussed during the call and a T-cell acute lymphoblastic leukemia study highlighted in the prior quarter.
- Gross Margin ImprovementThird-quarter 2026 adjusted gross margin was 48%, compared with 46% in Q3 2025. The company stated that adjusted gross margin had improved steadily from the low 20% range in 2023.
- Lower Operating ExpensesOperating expenses decreased 12% year-over-year to $10.5 million, while adjusted operating expenses decreased 9% to $8.8 million from $9.7 million in Q3 2025.
- Reiterated Full-Year Revenue GuidanceBionano reiterated full-year 2026 revenue guidance of $31 million to $33 million, representing growth of 9% to 16% over 2025, and expects to land near the midpoint of the range.
- Path Toward EBITDA NeutralityManagement stated that controlled expenses and rapid top-line growth are the main drivers of its goal to bring the company to EBITDA neutral in 2027, with adjusted EBITDA neutrality expected by the end of 2027.
- Planned Production Capacity ExpansionThe company has taken steps to address long lead times for critical components, including the silicon wafer containing the nanochannels. Management expects to approximately double current capacity by around the middle of 2027, which it said would more than meet projected 2027 capacity needs and most of 2028.
- Strategic Focus on Profitable GrowthSince September 2024, Bionano has shifted away from aggressive installed-base growth toward profitable growth with existing routine users, focusing on supporting routine OGM and VIA users, increasing utilization, building reimbursement support, and improving profitability and scalability.
MX:BNGO Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 10, 2027 | 2026 (Q4) | -7.25- | -28.81 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | -8.37-8.37 | -37.92 | 77.94% (+29.56) | |
| Aug 10, 2026 | 2026 (Q2) | -12.45-12.27 | -37.18 | 67.00% (+24.91) | |
| May 13, 2026 | 2026 (Q1) | -16.36-14.13 | -21.38 | 33.91% (+7.25) | |
| Mar 23, 2026 | 2025 (Q4) | -46.01-28.81 | -225.58 | 87.23% (+196.77) | |
| Nov 13, 2025 | 2025 (Q3) | -38.57-37.92 | -579.99 | 93.46% (+542.07) | |
| Aug 14, 2025 | 2025 (Q2) | -49.39-37.18 | -267.69 | 86.11% (+230.51) | |
| May 14, 2025 | 2025 (Q1) | ―- | -669.22 | ― | |
| Mar 31, 2025 | 2024 (Q4) | -56.20-21.38 | -669.22 | 96.81% (+647.84) | |
| Nov 13, 2024 | 2024 (Q3) | -220.30-579.99 | -3591.48 | 83.85% (+3011.49) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
